Compound that prevents replication of SARS-CoV-2 identified by researchers
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have found that the PI3K signalling pathway could be targeted to prevent liptoxicity and combat obesity.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
In rhesus macaques, a team were able to induce neural regeneration from brain internal glial cells, repairing damage from stroke.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
Researchers have shown that the internal clock controls the regenerative mechanism behind beta cells in diabetic mice.